Saturday, July 11, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Oncology R&D Pipeline

Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Programs 5,539

Quick answer

Oncology: NovaPharmaNews indexes 5,539 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Top sponsors

Pipeline programs

Page 27 of 116

  1. radiation therapy

    United Therapeutics Europe Ltd

    Bladder Cancer

    phase 3 other completed

    1 trial

  2. ramucirumab

    Eli Lilly and Company

    Gastric Cancer

    phase 3 mab completed

    1 trial

  3. recombinant human erythropoietin

    The First People's Hospital of Lianyungang

    Lymphoma

    phase 3 small molecule active

    1 trial

  4. recombinant interferon alfa

    United Therapeutics Europe Ltd

    Melanoma (Skin)

    phase 3 mab completed

    1 trial

  5. robot-assisted surgery

    Hospital Authority, Hong Kong

    Rectal Cancer

    phase 3 other active

    1 trial

  6. serplulimab、bevacizumab

    Changhai Hospital

    Rectal Cancer

    phase 3 small molecule active

    1 trial

  7. sunitinib malate

    Pfizer

    Carcinoma, Hepatocellular

    phase 3 small molecule terminated

    1 trial

  8. talazoparib plus enzalutamide

    Pfizer

    Prostate Cancer

    phase 3 small molecule active

    1 trial

  9. tissue-of-origin (ORIGIN-PanCA○R) profiling

    Fudan University

    Cancer of Unknown Primary Site

    phase 3 gene therapy completed

    1 trial

  10. toripalimab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Esophageal Cancer

    phase 3 small molecule active

    1 trial

  11. trastuzumab

    United Therapeutics Europe Ltd

    Breast Cancer

    phase 3 mab active

    1 trial

  12. trifluridine/tipiracil

    Takeda

    Metastatic Oesogastric Adenocarcinoma

    phase 3 small molecule active

    1 trial

  13. venetoclax

    The First People's Hospital of Lianyungang

    Acute Promyelocytic Leukemia

    phase 3 small molecule active

    1 trial

  14. vinflunine

    Pierre Fabre Medicament

    Breast Cancer

    phase 3 small molecule completed

    1 trial

  15. volrustomig

    AstraZeneca

    Locally Advanced Head and Neck Squamous Cell Carcinoma

    phase 3 small molecule active

    1 trial

  16. xevinapant, Xevinapant Placebo

    Merck Sharp and Dohme

    Resected squamous cell carcinoma of the head and neck

    phase 3 small molecule active

    1 trial

  17. zanubrutinib

    BEONE MEDICINES AUS PTY LTD

    Mantle Cell Lymphoma; Non-Hodgkin Lymphoma

    phase 3 small molecule active

    1 trial

  18. zongertinib

    Boehringer Ingelheim

    Lung Cancer, Non-squamous, Non-small Cell

    phase 3 small molecule active

    1 trial

  19. (Z)-endoxifen

    ATOSSA THERAPEUTICS, INC.

    Breast Neoplasms

    phase 2 small molecule active

    1 trial

  20. -

    Talion

    Primary or advanced breast cancer LumA or ER+ Lobular subtypes.

    phase 2 small molecule active

    1 trial

  21. -

    Ningbo Cancer Hospital

    Unresectable intrahepatic cholangiocarcinoma

    phase 2 small molecule active

    1 trial

  22. -

    Disc Medicine

    Intrahepatic cholangiocarcinoma (iCCA)

    phase 2 small molecule active

    1 trial

  23. -, Pred Forte 10 mg/ml colirio en suspensión

    AbbVie Deutschland GmbH & Co. KG

    platinum-resistant advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers.

    phase 2 small molecule active

    1 trial

  24. 1-(3-(fluoro-18F)benzyl)guanidine ([18F]mFBG)

    Disc Medicine

    Pheochromocytoma – endocrine adrenal tumor

    phase 2 small molecule active

    1 trial

  25. 1/BOB1

    Disc Medicine

    B-cell Acute Lymphoblastic Leukemia, Multiple Myeloma, Non-Hodgkin B-cell lymphoma

    phase 2 small molecule active

    1 trial

  26. 12.5mg sunitinib with Cisplatin and Gemcitabine

    Hospital Authority, Hong Kong

    Nasopharyngeal Carcinoma

    phase 2 small molecule completed

    1 trial

  27. 13914704178

    The First People's Hospital of Lianyungang

    Locally Advanced Esophageal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  28. 1479-0012

    Boehringer Ingelheim

    gastroesophageal junction adenocarcinoma, metastatic gastric adenocarcinoma, metastatic breast cancer, metastatic colorectal cancer, esophageal adenocarcinoma

    phase 2 small molecule active

    1 trial

  29. 1537-LYMG

    Ningbo Cancer Hospital

    Advanced stage Hodgkin Lymphoma

    phase 2 small molecule active

    1 trial

  30. 1570-CL-0101

    Astellas Pharma GmbH

    Advanced Solid Tumors

    phase 2 small molecule active

    1 trial

  31. 17000139BLC2001

    Janssen-Cilag International N.V.

    Non-Muscle-Invasive Urothelial Carcinoma (NMIBC) of the Bladder

    phase 2 small molecule active

    1 trial

  32. 17000139BLC2002

    Janssen-Cilag International N.V.

    Muscle-Invasive Urothelial Carcinoma of the Bladder

    phase 2 small molecule active

    1 trial

  33. 177Lu girentuximab

    Telix Innovations

    Advanced Cancer

    phase 2 small molecule active

    1 trial

  34. 177Lu-DOTA-EB-FAPI radionuclide therapy

    The First People's Hospital of Lianyungang

    Refractory Solid Tumor

    phase 2 small molecule completed

    1 trial

  35. 177Lu-DOTA-TLX591

    Telix Innovations

    Prostate Cancer

    phase 2 mab completed

    1 trial

  36. 177Lu-J591

    United Therapeutics Europe Ltd

    Prostate Cancer

    phase 2 small molecule active

    1 trial

  37. 177Lu-PSMA I&T_IRSTIRCCS

    Istituto Gentili S.r.l.

    Oligometastatic prostate carcinoma

    phase 2 small molecule active

    1 trial

  38. 177Lu-PSMA-617

    United Therapeutics Europe Ltd

    Metastatic Hormone Naive Prostate Cancer

    phase 2 small molecule active

    1 trial

  39. 1801

    ACTUATE THERAPEUTICS, INC.

    Refractory Hematologic Malignancies or Solid Tumors

    phase 2 small molecule active

    1 trial

  40. 19310

    Disc Medicine

    Head and neck squamous cell carcinoma (HNSCC)

    phase 2 other active

    1 trial

  41. 2-deoxyglucose

    United Therapeutics Europe Ltd

    Prostate Cancer

    phase 2 small molecule terminated

    1 trial

  42. 20-27 PaTcH

    Ningbo Cancer Hospital

    Metastatic refractory Pancreatic Cancer

    phase 2 small molecule active

    1 trial

  43. 2016/2369

    The George Institute

    pediatric cancer

    phase 2 small molecule active

    1 trial

  44. 2017/2558

    The George Institute

    Resectable mucosal melanomas

    phase 2 small molecule active

    1 trial

  45. 20170512

    The First People's Hospital of Lianyungang

    Triple-Negative Breast Cancer

    phase 2 small molecule completed

    1 trial

  46. 20180257

    Amgen

    Relapsed or Refractory B cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL) and Minimal Residual Disease Positive (MRD+) B-ALL,

    phase 2 small molecule active

    1 trial

  47. 2020-004696-41

    The George Institute

    Newly diagnosed, non-metastatic early-stage triple-negative or HER2+ breast cancer

    phase 2 small molecule active

    1 trial

  48. 2020-S112

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Uterine Cervical Neoplasm

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many oncology pipeline programs are tracked?

5,539 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.